BC022687 Activators
BC022687 activators represent a chemical class designed to selectively augment the activity of the molecular target identified as BC022687. The initial phase in the development of these activators involves high-throughput screening (HTS), where a diverse chemical library is meticulously tested for compounds that can activate BC022687. This screening employs sophisticated assays that can precisely detect the activation of BC022687 through quantifiable signals, such as enhanced fluorescence or luminescence. These signals indicate the success of a compound in increasing the activity of BC022687, and compounds that stand out during this process are marked for further investigation. The secondary screening phase involves more refined assays tailored specifically to the BC022687 target. These assays confirm the primary HTS results and validate the compounds as true activators by demonstrating their specific interaction with BC022687 and their capacity to upregulate its activity.
Upon the successful identification of potential BC022687 activators, detailed studies are conducted to unravel the interaction between these compounds and BC022687. Structural determination techniques, such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, are employed to discern the three-dimensional arrangement of these activators when bound to BC022687. Understanding the molecular structure of the activator-BC022687 complex is crucial for identifying the mechanism of activation and for the design of more effective activators. These studies can reveal the exact binding sites, the orientation of the compounds within these sites, and any structural changes in BC022687 that are associated with activation. In parallel, quantitative biophysical methods, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), provide essential data regarding the strength and kinetics of the interaction between BC022687 and its activators. These methods assess how strongly and quickly the activators bind to BC022687, which is critical for understanding their efficacy.
SEE ALSO...
Items 11 to 11 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may impact signaling pathways by reducing phosphorylation events. If "BC022687" is regulated by a tyrosine kinase-dependent pathway, genistein could indirectly enhance the functional activity of "BC022687"BC022687 Activators encompass a variety of chemical compounds that, through distinct signaling pathways, indirectly augment the functional activity of BC022687. Forskolin, a direct adenylyl cyclase activator, increases intracellular cAMP levels, which in turn enhances protein kinase A (PKA) activity. This elevation of PKA activity may result in the phosphorylation and consequent activation of BC022687, assuming it is a substrate or is regulated by PKA-mediated signaling. Similarly, IBMX acts to maintain cAMP levels by inhibiting phosphodiesterases, leading to a sustained activation of PKA and potential downstream effects on BC022687. PMA, an activator of protein kinase C (PKC), modifies signaling through PKC-dependent phosphorylation events that could include the activation of BC022687. Epigallocatechin gallate (EGCG), through kinase inhibition, may alter cellular signaling cascades in a manner that favors the activation of BC022687. | ||||||